Cargando…

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities

Detalles Bibliográficos
Autores principales:	Nichols, Dave P., Durmowicz, Anthony G., Field, Ann, Flume, Patrick A., VanDevanter, Donald R., Mayer-Hamblett, Nicole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2019
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491060/ https://www.ncbi.nlm.nih.gov/pubmed/30658043 http://dx.doi.org/10.1513/AnnalsATS.201812-863OT

Ejemplares similares

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis
por: Mayer-Hamblett, Nicole, et al.
Publicado: (2016)

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials
por: VanDevanter, Donald R., et al.
Publicado: (2021)

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review
por: VanDevanter, Donald R, et al.
Publicado: (2011)

State of progress in treating cystic fibrosis respiratory disease
por: Flume, Patrick A, et al.
Publicado: (2012)

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations
por: VanDevanter, Donald R, et al.
Publicado: (2010)

157: C-reactive protein (CRP) as a biomarker of exacerbation presentation and treatment response
por: VanDevanter, D., et al.
Publicado: (2021)

Optimising inhaled mannitol for cystic fibrosis in an adult population
por: Flume, Patrick A., et al.
Publicado: (2015)

Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis
por: Carmody, Lisa A., et al.
Publicado: (2018)

A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis
por: Paynter, Alex, et al.
Publicado: (2022)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

Eradication of early MRSA infection in cystic fibrosis: a novel study design for the STAR-ter trial
por: Cunningham, Fiona, et al.
Publicado: (2022)

Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time
por: Crull, Mathew R., et al.
Publicado: (2016)

Use of inhaled antibiotics among Danish patients with cystic fibrosis
por: Møller, Rikke, et al.
Publicado: (2022)

Future therapies for cystic fibrosis
por: Allen, Lucy, et al.
Publicado: (2023)

The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network
por: Pearson, Kelsie, et al.
Publicado: (2021)

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis
por: Li, Danni, et al.
Publicado: (2023)

Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives
por: Taccetti, Giovanni, et al.
Publicado: (2021)

The Impact of COVID-19 in Cystic Fibrosis
por: Flume, Patrick A., et al.
Publicado: (2022)

Opportunities and challenges in the current era of global medical education
por: Rizwan, Muhammad, et al.
Publicado: (2018)

The emergence of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis patients on inhaled antibiotics
por: AbdulWahab, Atqah, et al.
Publicado: (2017)

Inhaled Biologicals for the Treatment of Cystic Fibrosis
por: Sala, Valentina, et al.
Publicado: (2019)

Risk of Development of Resistance in Patients with Non-Cystic Fibrosis Bronchiectasis Treated with Inhaled Antibiotics
por: Regan, Kate H., et al.
Publicado: (2018)

Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis
por: Xu, Meng-Jiao, et al.
Publicado: (2020)

One versus Many: Polymicrobial Communities and the Cystic Fibrosis Airway
por: Jean-Pierre, Fabrice, et al.
Publicado: (2021)

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
por: Heirali, Alya A., et al.
Publicado: (2017)

Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis
por: Guo, Mengqin, et al.
Publicado: (2023)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
por: Elson, Elizabeth Claire, et al.
Publicado: (2019)

Translational Metabolomics: Current Challenges and Future Opportunities
por: Pinu, Farhana R., et al.
Publicado: (2019)

Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?
por: Karki, Kumar, et al.
Publicado: (2021)

Role of inhaled antibiotics in children and adolescents with cystic fibrosis: Experience from the tertiary care center
por: Aziz, Danish Abdul, et al.
Publicado: (2022)

With newer tools for gene editing, is it time to revisit genetic therapy for cystic fibrosis?
por: Gupta, Anuj, et al.
Publicado: (2020)

CFTR modulators: transformative therapies for cystic fibrosis
por: Dwight, Mary, et al.
Publicado: (2021)

LasR Variant Cystic Fibrosis Isolates Reveal an Adaptable Quorum-Sensing Hierarchy in Pseudomonas aeruginosa
por: Feltner, John B., et al.
Publicado: (2016)

In Vitro Inhibition of Neutrophil Elastase Activity by Inhaled Anti-Pseudomonas Antibiotics Used in Cystic Fibrosis Patients
por: Hector, Andreas, et al.
Publicado: (2010)

The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis
por: Dhand, Rajiv
Publicado: (2018)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Inhaled therapy in cystic fibrosis: agents, devices and regimens
por: Agent, Penny, et al.
Publicado: (2015)

Nebulizer Care and Inhalation Technique in Children with Cystic Fibrosis
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
por: Han, Xiaoxuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iqh2nbm914ontgfa8ital4ju33